BRPI1010511A2 - composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva - Google Patents
composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetivaInfo
- Publication number
- BRPI1010511A2 BRPI1010511A2 BRPI1010511-5A BRPI1010511A BRPI1010511A2 BR PI1010511 A2 BRPI1010511 A2 BR PI1010511A2 BR PI1010511 A BRPI1010511 A BR PI1010511A BR PI1010511 A2 BRPI1010511 A2 BR PI1010511A2
- Authority
- BR
- Brazil
- Prior art keywords
- schizophrenia
- patient
- composition
- risk
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiv a" é descrita uma composição para distribuição de um medicamento. a composição tem um revestimento semipermeável, partículas de clozapina tendo um tamanho de partícula médio efetivo de menos que ou cerca de 2 f..lm e pelo menos um estabilizante de superfície adsorvido na superfície das partículas de clozapina, e um agente solubilizante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16804009P | 2009-04-09 | 2009-04-09 | |
US61/168040 | 2009-04-09 | ||
PCT/US2010/030393 WO2010118232A1 (en) | 2009-04-09 | 2010-04-08 | Controlled-release clozapine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1010511A2 true BRPI1010511A2 (pt) | 2019-04-09 |
Family
ID=42934579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1010301A BRPI1010301A2 (pt) | 2009-04-09 | 2010-04-08 | composição. |
BRPI1010511-5A BRPI1010511A2 (pt) | 2009-04-09 | 2010-04-08 | composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1010301A BRPI1010301A2 (pt) | 2009-04-09 | 2010-04-08 | composição. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20100260858A1 (pt) |
EP (2) | EP2416782A1 (pt) |
JP (4) | JP2012523428A (pt) |
KR (1) | KR20120022895A (pt) |
CN (2) | CN102448447A (pt) |
AU (2) | AU2010234339B2 (pt) |
BR (2) | BRPI1010301A2 (pt) |
CA (2) | CA2758258A1 (pt) |
IL (1) | IL215608A0 (pt) |
MX (2) | MX2011010620A (pt) |
NZ (1) | NZ595691A (pt) |
RU (3) | RU2011145278A (pt) |
SG (1) | SG175137A1 (pt) |
TW (2) | TWI546088B (pt) |
WO (2) | WO2010118232A1 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2416782A1 (en) * | 2009-04-09 | 2012-02-15 | Alkermes Pharma Ireland Limited | Controlled-release clozapine compositions |
CN102427834A (zh) | 2009-04-28 | 2012-04-25 | 苏尔莫迪克斯公司 | 用于递送生物活性剂的装置和方法 |
US20110172210A1 (en) * | 2010-01-13 | 2011-07-14 | Azur Pharma Limited | Method for titrating clozapine |
US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
US10010514B2 (en) * | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US10213529B2 (en) * | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US9757497B2 (en) * | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
WO2014043693A1 (en) * | 2012-09-17 | 2014-03-20 | Tarix Pharmaceuticals Ltd. | Oral formulations of angiotensin |
US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
US9555119B2 (en) | 2012-11-05 | 2017-01-31 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
RU2696559C2 (ru) | 2013-03-14 | 2019-08-05 | Селтакссис, Инк. | Ингибиторы лейкотриен а4-гидролазы |
TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事(everolimus)之醫藥組合物 |
CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
KR102274297B1 (ko) * | 2014-11-06 | 2021-07-07 | 주식회사 엘지생활건강 | 옥틸갈레이트를 함유하는 화장료 조성물 |
EA201792314A1 (ru) | 2015-05-20 | 2018-05-31 | Новартис Аг | Фармацевтическая комбинация эверолимуса и дактолисиба |
KR101884230B1 (ko) * | 2016-02-29 | 2018-08-01 | 주식회사 유영제약 | 에소메프라졸을 포함하는 제제 |
SG11201811351WA (en) * | 2016-07-05 | 2019-01-30 | Timilon Tech Acquisitions Llc | Compositions and methods for forming stable, liquid metal oxide/hydroxide formulations |
BR112019004892A2 (pt) * | 2016-09-17 | 2019-06-11 | Intas Pharmaceuticals Ltd | composição farmacêutica de liberação prolongada de clozapina sob a forma de multiparticulados, e processo para a preparação de uma composição farmacêutica de liberação prolongada de clozapina |
JP6957610B2 (ja) * | 2016-10-06 | 2021-11-02 | スキャンポ・アーゲーSucampo AG | 医薬品用途のための多層ビーズ |
CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
US11534397B2 (en) * | 2017-11-09 | 2022-12-27 | The Board Of Regents Of The University Of Oklahoma | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
CN108371728B (zh) * | 2018-03-09 | 2020-12-18 | 西南交通大学 | 一种用于组织修复的仿贻贝接触抗菌水凝胶的制备方法 |
CN108295264A (zh) * | 2018-03-28 | 2018-07-20 | 五邑大学 | 聚乙烯吡咯烷酮k12的应用 |
US11672781B2 (en) | 2018-05-07 | 2023-06-13 | Prana Biosciences Inc | Metaxalone formulations |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
CN109602952B (zh) * | 2018-12-27 | 2021-05-18 | 上海北陆医药科技有限公司 | 一种长效缓释细胞支架及其制备方法、应用 |
US11918590B2 (en) * | 2021-12-15 | 2024-03-05 | Intas Pharmaceuticals Ltd. | Stable extended release pharmaceutical composition of clozapine |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (pt) * | 1960-11-29 | |||
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
DE1720701A1 (de) * | 1967-08-22 | 1971-07-15 | Bayer Ag | Vernetzbare Lackharze |
FR2000803A1 (pt) * | 1968-01-26 | 1969-09-12 | Kalle Ag | |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3615024A (en) * | 1968-08-26 | 1971-10-26 | Amicon Corp | High flow membrane |
BE758820A (fr) * | 1969-11-13 | 1971-05-12 | Celanese Corp | Procede de production de pellicules microporeuses a cellules ouvertes |
FR2105306A5 (pt) * | 1970-08-07 | 1972-04-28 | Rhone Poulenc Sa | |
CA984567A (en) * | 1972-02-16 | 1976-03-02 | Albert E. Smith | Microporous polymer sheets |
US3852224A (en) * | 1972-09-14 | 1974-12-03 | Tee Pak Inc | Microporous films |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
US4971790A (en) * | 1986-02-07 | 1990-11-20 | Alza Corporation | Dosage form for lessening irritation of mocusa |
US4801461A (en) * | 1987-01-28 | 1989-01-31 | Alza Corporation | Pseudoephedrine dosage form |
GB8717168D0 (en) * | 1987-07-21 | 1987-08-26 | Roussel Lab Ltd | Controlled-release device |
US4946686A (en) * | 1987-09-24 | 1990-08-07 | Merck & Co., Inc. | Solubility modulated drug delivery system |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
DK0914097T3 (da) * | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
DE19635676A1 (de) * | 1996-09-03 | 1998-03-05 | Basf Ag | Feste geschäumte Wirkstoffzubereitungen |
ATE314054T1 (de) * | 1996-10-25 | 2006-01-15 | Shire Lab Inc | Osmotisches verabreichungssystem für lösliche dosen |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
DK1035834T3 (da) * | 1997-12-05 | 2002-07-08 | Alza Corp | Osmotisk doseringsform omfattende en første og anden coating |
EP1049424A4 (en) * | 1998-01-06 | 2001-11-28 | Nicholas A Sceusa | MEDICINE DOSAGE BASED ON THE TEORELL MAYER GRADIENT |
US6004584A (en) * | 1998-03-02 | 1999-12-21 | The Procter & Gamble Company | Highly absorbent body powders |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
CN1161101C (zh) * | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
AU1444301A (en) * | 1999-10-29 | 2001-05-14 | Merck & Co., Inc. | Osmotic controlled release drug delivery device |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
TW200302748A (en) * | 2002-02-01 | 2003-08-16 | Pfizer Prod Inc | Osmotic delivery system |
US20040018242A1 (en) * | 2002-05-06 | 2004-01-29 | Elan Pharma International Ltd. | Nanoparticulate nystatin formulations |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
US7611728B2 (en) * | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
JP2007516297A (ja) * | 2003-12-23 | 2007-06-21 | アルザ・コーポレーシヨン | 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物 |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
CN101132768A (zh) * | 2004-12-15 | 2008-02-27 | 伊兰制药国际有限公司 | 纳米颗粒他克莫司制剂 |
JP2008531721A (ja) * | 2005-03-03 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | 複素環式アミド誘導体のナノ粒子状組成物 |
EP1931632A4 (en) * | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
AU2006318349B2 (en) * | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
RU2428176C2 (ru) * | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
KR101413613B1 (ko) * | 2006-01-27 | 2014-07-10 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 선택성 세로토닌 5-ht3 차단제와 유기산을 포함하는 약물 전달 시스템 |
CA2661683C (en) * | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
TWI519322B (zh) * | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
RU2403041C2 (ru) * | 2008-12-18 | 2010-11-10 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Лекарственное средство пролонгированного действия с дозированным высвобождением в органы-мишени на основе d-циклосерина для лечения резистентных форм туберкулеза |
EP2416782A1 (en) * | 2009-04-09 | 2012-02-15 | Alkermes Pharma Ireland Limited | Controlled-release clozapine compositions |
-
2010
- 2010-04-08 EP EP10762437A patent/EP2416782A1/en not_active Withdrawn
- 2010-04-08 CN CN201080023470XA patent/CN102448447A/zh active Pending
- 2010-04-08 US US12/757,005 patent/US20100260858A1/en not_active Abandoned
- 2010-04-08 WO PCT/US2010/030393 patent/WO2010118232A1/en active Application Filing
- 2010-04-08 US US12/757,024 patent/US20100260859A1/en not_active Abandoned
- 2010-04-08 CN CN201610091458.1A patent/CN105581984A/zh active Pending
- 2010-04-08 MX MX2011010620A patent/MX2011010620A/es unknown
- 2010-04-08 WO PCT/US2010/030387 patent/WO2010118228A1/en active Application Filing
- 2010-04-08 RU RU2011145278/15A patent/RU2011145278A/ru not_active Application Discontinuation
- 2010-04-08 CA CA2758258A patent/CA2758258A1/en not_active Abandoned
- 2010-04-08 AU AU2010234339A patent/AU2010234339B2/en not_active Ceased
- 2010-04-08 JP JP2012504864A patent/JP2012523428A/ja not_active Withdrawn
- 2010-04-08 BR BRPI1010301A patent/BRPI1010301A2/pt not_active IP Right Cessation
- 2010-04-08 SG SG2011073517A patent/SG175137A1/en unknown
- 2010-04-08 EP EP10762434.8A patent/EP2416764A4/en not_active Withdrawn
- 2010-04-08 MX MX2011010621A patent/MX2011010621A/es not_active Application Discontinuation
- 2010-04-08 NZ NZ595691A patent/NZ595691A/xx not_active IP Right Cessation
- 2010-04-08 JP JP2012504860A patent/JP2012523427A/ja active Pending
- 2010-04-08 CA CA2757979A patent/CA2757979A1/en not_active Abandoned
- 2010-04-08 RU RU2011145279/15A patent/RU2589823C2/ru not_active IP Right Cessation
- 2010-04-08 RU RU2016120727A patent/RU2016120727A/ru not_active Application Discontinuation
- 2010-04-08 KR KR1020117026643A patent/KR20120022895A/ko not_active Application Discontinuation
- 2010-04-08 AU AU2010234343A patent/AU2010234343A1/en not_active Abandoned
- 2010-04-08 BR BRPI1010511-5A patent/BRPI1010511A2/pt not_active IP Right Cessation
- 2010-04-09 TW TW099111212A patent/TWI546088B/zh not_active IP Right Cessation
- 2010-04-09 TW TW099111214A patent/TW201039867A/zh unknown
-
2011
- 2011-10-06 IL IL215608A patent/IL215608A0/en unknown
-
2014
- 2014-09-08 JP JP2014182031A patent/JP5934312B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-22 US US14/746,035 patent/US20150283092A1/en not_active Abandoned
-
2016
- 2016-05-06 JP JP2016092931A patent/JP2016138136A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1010511A2 (pt) | composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva | |
BRPI0415397A (pt) | métodos e reagentes para o tratamento de desordens imunoinflamatórias | |
BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
BR0307772A (pt) | Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência | |
CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
BR112015023425A2 (pt) | método e composição para coloração e processamento de uma amostra de urina | |
BR112015032813A2 (pt) | método de tratamento de uma zona de tratamento de um poço, e, composição | |
BR112014012555A2 (pt) | toner magnético | |
BRPI0900738A2 (pt) | descontaminação de área via concentração em baixo nìvel de agente germicida | |
BRPI0705488A (pt) | composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem | |
BRPI0915986A2 (pt) | composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo | |
BRPI0923859B8 (pt) | composição de agente de diagnóstico, e, método para a produção das nanopartículas | |
BRPI0419048A (pt) | composição útil para fornecer revestimento de remoção de nox sobre a superfìcie material | |
WO2007103373A3 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
BRPI0818911A2 (pt) | Composição, processo para a preparação de bronze de hidrogênio e tungstênio ou de uma composição de bronze de hidrogênio e tungstênio, dispersão de partícula, e, uso de partículas de bronze de hidrogênio e tungstênio ou de partículas que contenham bronze de hidrogênio e tungstênio | |
CL2009000647A1 (es) | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. | |
BR112014012711A2 (pt) | preservativo revestido | |
CO6280502A2 (es) | Una composicion farmaceutica | |
BRPI0701802A2 (pt) | cassete cirérgico com zona de grampeamento complacente | |
WO2008133928A3 (en) | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders | |
BRPI0607280A2 (pt) | método de tratamento ou prevenção de capsulite adesiva em paciente com necessidade desse tratamento | |
BR112017015008A2 (pt) | trilho | |
BR112014030394A2 (pt) | superfície de piso magnético | |
BR112014031528A2 (pt) | composição compreendendo polímero super absorvente | |
BR112018011481A2 (pt) | método para tratar um efluente aquoso, uso de pelo menos um agente, uso de pelo menos um agente de dispersão sulfonado e composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |